OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Arlene Sharpe on the Role of the PD-1 Pathway

January 7th 2016

Arlene Sharpe, MD, PhD, immunology faculty member, Harvard Medical School, discusses the biology of the PD-1 pathway.

Dr. Swords on Anti-Tumor Effects of IMG-98 in AML

January 6th 2016

Ronan T. Swords, MD, discusses preclinical findings demonstrating that the small-molecule inhibitor IMG-98 effectively augments pro-differentiation effects of all-trans-retinoic acidâ€“based therapies in acute myeloid leukemia.

Dr. Murphy on Glioma Prognostic Factors in Younger Patients

January 6th 2016

Erin Murphy, MD, associate staff, Department of Radiation Oncology, Cleveland Clinic, discusses a study examining prognostic factors of patients with glioma.

Dr. Mamounas on Future of Surgical Treatments in Breast Cancer

January 5th 2016

Eleftherios P. Mamounas, MD, surgical oncologist, UF Health Cancer Center - Orlando Health, shares the future of surgical treatments for patients with breast cancer.

Dr. Goodman on Ongoing Clinical Trials in Radiation Oncology

January 5th 2016

Karyn A. Goodman, MD, radiation oncologist, professor in the Department of Radiation Oncology, University of Colorado Denver, discusses ongoing trials in the field of radiation oncology.

Dr. Luke on the Future of Combination Therapy in Melanoma

January 5th 2016

Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses what the future holds for combination therapies for patients with melanoma.

Dr. Hofmeister on Reolysin Combined With Carfilzomib for Multiple Myeloma

January 4th 2016

Craig Hofmeister, MD, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University, discusses a study that examined the efficacy of reolysin combined with carfilzomib in patients with relapsed multiple myeloma.

Dr. Pecora on RCCA's New Business and Science Approaches

January 1st 2016

Andrew L. Pecora, MD, FACP, CPE, chief innovations officer, professor, vice president of Cancer Services, John Theurer Cancer Center at Hackensack University Medical Center, president, Regional Cancer Care Associates (RCCA), LLC, discusses new business and science approaches RCCA has taken to better provide value-based care to patients.

Dr. Rizzo on Impact of Age on Survival Outcomes in MDS After HCT

December 31st 2015

J. Douglas Rizzo, MD, MS, assistant scientific professor, Center for International Blood and Marrow Transplant Research, professor of Medicine, Medical College of Wisconsin, discusses a study that examined if age affects survival outcomes in patients with myelodysplastic syndromes who receive a hematopoietic cell transplant.

Demmie Aguilar on Selecting a Clinical Trial Site

December 30th 2015

Demmie Aguilar, research coordinator, Clinical Research Division, Regional Cancer Care Associates, LLC, Central Jersey Division, discusses the qualities pharmaceutical companies look for when selecting a clinical trial site.

Dr. Lonial on Novel Mechanisms in Multiple Myeloma

December 29th 2015

Sagar Lonial, MD, chief medical officer at Winship Cancer Institute of Emory University, discusses novel mechanisms of agents used for the treatment of patients with multiple myeloma.

Dr. Wiesner on Importance of Genetic Testing for CRC

December 28th 2015

Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, discusses the importance of genetic testing for colorectal cancer.

Dr. Ciezki on Common Advanced Disease Sites in Patients

December 24th 2015

Jay Ciezki, MD, Department of Radiation Oncology, Cleveland Clinic, discusses an analysis of patients with various malignancies who commonly presented with advanced disease.

Dr. Wu on Possible Combinations With TAS-102 in CRC

December 23rd 2015

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses potential combinations with TAS-102 for the treatment of patients with colorectal cancer.

Dr. Figlin on Advice for Oncologists Treating RCC

December 22nd 2015

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, provides advice to community oncologists who are treating patients with renal cell carcinoma.

Dr. Stein on Blinatumomab for Relapsed/Refractory ALL

December 22nd 2015

Anthony S. Stein, MD, professor and staff physician, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope, discusses a phase II study examining blinatumomab in relapsed/refractory patients with Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.

Dr. John Marshall on Steps to Finding a Cure for Colorectal Cancer

December 21st 2015

John Marshall, MD, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses curing colorectal cancer.

Dr. Visani on Tosedostat and Cytarbine in Elderly Patients With AML

December 21st 2015

Guiseppe Visani, MD, director, Hematology and Stem Cell Transplant Center at AORMN, Pesaro, Italy, discusses a phase II study examining the efficacy of tosedostat plus low-dose cytarabine in elderly patients with acute myeloid leukemia.

Dr. Sharman on Entospletinib in Patients With CLL

December 18th 2015

Jeff Sharman, MD, director of Research with Willamette Valley Cancer Institute and Research Center, medical director of Hematology Research for The US Oncology Network, discusses clinical activity of entospletinib in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who were previously treated with a B-cell receptor pathway signaling inhibitor.

Dr. Antonarakis on Galeterone for Prostate Cancer

December 17th 2015

Emmanuel Antonarakis, MBBCh, associate professor of Oncology, associate professor of Urology at Johns Hopkins Medicine, discusses the use of galeterone in prostate cancer.